Comparison of Anti-SARS-CoV-2-Specific Antibody Signatures in Maternal and Infant Blood after COVID-19 Infection versus COVID-19 Vaccination during Pregnancy

Abstract

Objective The Advisory Committee on Immunization Practices and The American College of Obstetricians and Gynecologists recommend coronavirus disease 2019 (COVID-19) vaccine for pregnant persons to prevent severe illness and death. The objective was to examine levels of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) IgG, IgM, and IgA against spike protein receptor binding domain (RBD) and nucleocapsid protein (NCP) in maternal and infant/cord blood at delivery after COVID 19 vaccination compared with SARS-CoV-2 infection at in mother–infant dyads at specified time points.

Study Design Mothers with SARS-CoV-2 infection (n = 31) or COVID-19 vaccination (n = 25) during pregnancy were enrolled between July 2020 and November 2021. Samples were collected at delivery and IgG, IgM, and IgA to RBD of spike and NCPs compared in the infected and vaccinated groups. Timing of infection/vaccination prior to delivery and correlation with antibody levels was performed.

Results The majority of participants received vaccination within 90 days of delivery and over half received the Pfizer BioNTech vaccine. There were no significant correlations between antibody levels and timing of infection or vaccination. Infant IgG levels to the RBD domain of spike protein were higher in the vaccinated group (n = 25) as compared with the infants born to mothers with infection (n = 31). Vaccination against COVID-19 during pregnancy was associated with detectable maternal and infant anti-RBD IgG levels at delivery irrespective of the timing of vaccination.

Conclusion Timing of vaccination had no correlation to the antibody levels suggesting that the timing of maternal vaccination in the cohort did not matter. There was no IgM detected in infants from vaccinated mothers. Infants from vaccinated mothers had robust IgG titers to RBD, which have a lasting protective effect in infants.

Key Points

• COVID-19 vaccination during pregnancy had detectable antibody.

• No correlation between antibody levels and timing of vaccination.

• Infants from vaccinated mothers had robust IgG titers to RBD.

Keywords

COVID-19 - vertical transmission - vaccination - vaccine - IgG - IgM - IgA

Publication History

Received: 28 October 2022

Accepted: 26 September 2023

Accepted Manuscript online:
29 September 2023

Article published online:
31 October 2023

• References

• 1 Allotey J, Stallings E, Bonet M. et al; for PregCOV-19 Living Systematic Review Consortium. Clinical manifestations, risk factors, and maternal and perinatal outcomes of coronavirus disease 2019 in pregnancy: living systematic review and meta-analysis. BMJ 2020; 370: m3320
• 2 Zambrano LD, Ellington S, Strid P. et al; CDC COVID-19 Response Pregnancy and Infant Linked Outcomes Team. Update: characteristics of symptomatic women of reproductive age with laboratory-confirmed SARS-CoV-2 infection by pregnancy status - United States, January 22-October 3, 2020. MMWR Morb Mortal Wkly Rep 2020; 69 (44) 1641-1647
• 3 Metz TD, Clifton RG, Hughes BL. et al; for the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Maternal-Fetal Medicine Units (MFMU) Network. Disease severity and perinatal outcomes of pregnant patients with coronavirus disease 2019 (COVID-19). Obstet Gynecol 2021; 137 (04) 571-580
• 4 Gray KJ, Bordt EA, Atyeo C. et al. Coronavirus disease 2019 vaccine response in pregnant and lactating women: a cohort study. Am J Obstet Gynecol 2021; 225 (03) 303.e1-303.e17
• 5 Prahl M, Golan Y, Cassidy AG. et al. Evaluation of transplacental transfer of mRNA vaccine products and functional antibodies during pregnancy and early infancy. Nat Commun 2022; 13 (01) 4422
• 6 Edlow AG, Li JZ, Collier AY. et al. Assessment of maternal and neonatal SARS-CoV-2 viral load, transplacental antibody transfer, and placental pathology in pregnancies during the COVID-19 pandemic. JAMA Netw Open 2020; 3 (12) e2030455
• 7 Fouda GG, Martinez DR, Swamy GK, Permar SR. The impact of IgG transplacental transfer on early life immunity. Immunohorizons 2018; 2 (01) 14-25
• 8 Beharier O, Plitman Mayo R, Raz T. et al. Efficient maternal to neonatal transfer of antibodies against SARS-CoV-2 and BNT162b2 mRNA COVID-19 vaccine. J Clin Invest 2021; 131 (13) e150319 Erratum in: J Clin Invest 2021;131(19)
• 9 Mithal LB, Otero S, Shanes ED, Goldstein JA, Miller ES. Cord blood antibodies following maternal coronavirus disease 2019 vaccination during pregnancy. Am J Obstet Gynecol 2021; 225 (02) 192-194
• 10 Abbasi J. Widespread misinformation about infertility continues to create COVID-19 vaccine hesitancy. JAMA 2022; 327 (11) 1013-1015
• 11 Taglauer ES, Dhole Y, Boateng J. et al. Evaluation of maternal-infant dyad inflammatory cytokines in pregnancies affected by maternal SARS-CoV-2 infection in early and late gestation. J Perinatol 2022; 42 (10) 1319-1327
• 12 Garcia-Flores V, Romero R, Xu Y. et al. Maternal-fetal immune responses in pregnant women infected with SARS-CoV-2. Nat Commun 2022; 13 (01) 320
• 13 Collier AY, McMahan K, Yu J. et al. Immunogenicity of COVID-19 mRNA vaccines in pregnant and lactating women. JAMA 2021; 325 (23) 2370-2380
• 14 Kohler PF, Farr RS. Elevation of cord over maternal IgG immunoglobulin: evidence for an active placental IgG transport. Nature 1966; 210 (5040) 1070-1071
• 15 Chi J, Gong W, Gao Q. Clinical characteristics and outcomes of pregnant women with COVID-19 and the risk of vertical transmission: a systematic review. Arch Gynecol Obstet 2021; 303 (02) 337-345
• 16 Sinaci S, Ocal DF, Seven B. et al. Vertical transmission of SARS-CoV-2: a prospective cross-sectional study from a tertiary center. J Med Virol 2021; 93 (10) 5864-5872
• 17 Sabharwal V, Bartolome R, Hassan SA. et al. Mother-infant dyads with COVID-19 at an urban, safety-net hospital: clinical manifestations and birth outcomes. Am J Perinatol 2021; 38 (07) 741-746
• 18 Yang YJ, Murphy EA, Singh S. et al. Association of gestational age at coronavirus disease 2019 (COVID-19) vaccination, history of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, and a vaccine booster dose with maternal and umbilical cord antibody levels at delivery. Obstet Gynecol 2022; 139 (03) 373-380
• 19 Bai Z, Cao Y, Liu W, Li J. The SARS-CoV-2 nucleocapsid protein and its role in viral structure, biological functions, and a potential target for drug or vaccine mitigation. Viruses 2021; 13 (06) 1115
• 20 Assis R, Jain A, Nakajima R. et al; Specimen Collection Group. Distinct SARS-CoV-2 antibody reactivity patterns elicited by natural infection and mRNA vaccination. NPJ Vaccines 2021; 6 (01) 132
• 21 Follmann D, Janes HE, Buhule OD. et al. Antinucleocapsid antibodies after SARS-CoV-2 infection in the blinded phase of the randomized, placebo-controlled mRNA-1273 COVID-19 vaccine efficacy clinical trial. Ann Intern Med 2022; 175 (09) 1258-1265
• 22 Carlsen EØ, Magnus MC, Oakley L. et al. Association of COVID-19 vaccination during pregnancy with incidence of SARS-CoV-2 infection in infants. JAMA Intern Med 2022; 182 (08) 825-831
• 23 Atyeo CG, Shook LL, Brigida S. et al. Maternal immune response and placental antibody transfer after COVID-19 vaccination across trimester and platforms. Nat Commun 2022; 13 (01) 3571